Neuralstem Appoints CEO
This article was originally published in Scrip
Executive Summary
Neuralstem, a company focused on therapies for the central nervous system, has appointed Richard J. Daly president, CEO and a member of the company's board of directors. Daly has more than 25 years' experience and will succeed Richard Garr, J.D., who was president and CEO since co-founding Neuralstem. Recently, Dale was managing director of Ravine Rock Partners, LLC. and interim chief commercial officer at Catalyst Pharma until Sept. 2015. He also led the turnaround initiatives of the Bristol-Myers Squibb and AstraZeneca plc's diabetes alliance whilst serving as president of the US diabetes subsidiary from 2013 through the AstraZeneca integration completion in 2014.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.